Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Thromboembolism
New thromboembolism study findings have been published by scientists at i3 Drug Safety
May 16th, 2008
According to a study from the United States, " Residual confounding is a potential limitation of pharmacoepidemiologic studies, and in particular, studies based on administrative claims data that do not capture lifestyle and clinical confounders. We describe an application of the case-cohort design to assess residual confounding by thromboembolic risk factors (e.g., smoking and obesity) not captured in claims data in a claims-based cohort study of thromboembolism among matched oral contraceptive (OC) initiators." " This study was conducted using the Ingenix Research Data Mart, a database containing medical claims for approximately 12 million members of a large health...
Source: Health Business Week (2008-05-16)
|
